You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy

    SBC: AFFIRMED PHARMA, LLC            Topic: NEI

    Abstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

    SBC: ARCASCOPE INC.            Topic: NHLBI

    ABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection

    SBC: Nutriforward, LLC            Topic: 100

    Project Summary Choroidal neovascularization (CNV) occurs in both age-related macular degeneration (AMD) and diabetic retinopathy (DR). While anti-VEGF treatment has improved the visual outcome considerably, they are far from achieving a 100% success rate (non-responsiveness between 8 and 50%). Inherited retinal degenerations (IRDs) are a group of heterogeneous, progressive, visually debilitating ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.

    SBC: SPACERX LLC            Topic: NIDA

    ABSTRACT Developing drugs that target the central nervous system (CNS) is hampered by an inability to perform direct in vivo preclinical measurements. Here, we propose to identify an optimal smoking cessation drug candidate by monitoring how our newly synthesized prodrugs alter real-time brain dopamine responses to nicotine. Varenicline (CHANTIX®) is the leading FDA-approved oral medication for s ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer

    SBC: WNTRIX INC            Topic: 102

    PROJECT SUMMARY Colorectal cancer is still a major cause of cancer-related death in the world and only a small subset of patients benefits from therapy by immune checkpoint inhibitors. Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specific ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing RNA therapeutics for rare neurodevelopmental disorders

    SBC: Dayi Therapeutics, Inc.            Topic: NICHD

    PROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD

    SBC: Aviara Pharmaceuticals, Inc.            Topic: 300

    Inflammatory bowel disease (IBD) is comprised mainly of Crohn’s Disease (CD) and Ulcerative Colitis (UC), and is characterized by a chronic non-resolving inflammatory response in the intestinal mucosa. Although the exact etiology is unknown, dysbiosis, genetic, environmental, and immunologic factors are all thought to play roles in this multifactorial disease. There are no cures, and in most cas ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage

    SBC: THE TINY CARGO COMPANY            Topic: 102

    Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects of cancer radiation therapy (RT). Our therapeutic is comprised of milk-derived extracellular vesicles (mEVs) loaded with a safe and highly effective radioprotective drug – a formulation that we call Milactatm. RT compli ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Genetic Biocontainment Switch to Improve the Safety of Drug Detoxifying Bacteria in Preventing Chemotherapy-induced Diarrhea

    SBC: SANARENTERO LLC            Topic: 102

    PROJECT SUMMARY Bioengineered microbes are a promising strategy to develop live biotherapeutic products that can introduce novel metabolic activities into the gut microbiome and digestive system for the prevention and treatment of several gut-related diseases/disorders. Sanarentero is developing novel drug detoxifying bacteria (DDB), which is a bioengineered live biotherapeutic product that can de ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. IND-enabling studies for cell therapy in Parkinson's disease

    SBC: NEONEURON LLC            Topic: 105

    Parkinson’s disease (PD) is a progressive neurodegenerative disease that is currently incurable with significant unmet medical needs. In the US, over a million people suffer from this disease with an estimated cost of $27 billion per year. The mainstay of PD management is symptomatic treatment with drugs that increase dopamine in the striatum. However, the utility of these drugs is significantly ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government